Seeking Alpha

Henry McCusker's  Instablog

Henry McCusker
Send Message
Editor and Publisher ... Henry enters his twelve (12) year at RegMed Investors which aggregates, curates and creates bottom-line content of regenerative medicine and cell therapy news providing a "vetted" selection of relevant and high-impact synthesis. He was VP - Strategic Planning... More
My company:
Scimitar Equity-Regenerative Medicine Investors
My blog:
Scimitar Equity Blog
  • BioLife Solutions (OTCBB: BLFS), Bio-preservation Technology Recognized By 50 + Client Usage 0 comments
    Oct 29, 2012 12:26 PM

    Bio-preservation Technology Recognized … by most clinical trial-stage cellular therapies

    BLFS' novel bio-preservation technology is being used in more than 50 clinical trial-stage cellular therapies, making it the leading choice in the emerging, high growth field of regenerative medicine.

    BLFS holds the number #1 supplier position among companies offering pre-formulated cell and tissue storage and freeze media used in clinical trial stage cellular therapies to treat the leading causes of death and disability such as cancer, heart disease, stroke, and joint/movement disorders.

    The Bottom Line: Cutting to the point - "When you are providing <critical reagents>, it is always better to integrate cumulative positive and negative yield … and cost impact .. in reference to … cryopreservation freeze media for cells and tissues, and contract aseptic media … "home brewing" is not the way to go". BLFS' revenue from its growing RegMed customer base, along with its selective targeting of contract manufacturing customers, should positive generate cash and profits as adaption continues and clients gain approvals. At that point, profitable growth should accelerate in a step-wise fashion. Recognition by … more companies and hospital-based transplant centers using pre-formulated storage, shipping, and freeze media products has come as BLFS has consistently converted these customers … from using 'home-brew' formulations to our cGMP, protein-free, serum-free biopreservation media products.Product shelf life and post-preservation viability are critical to good clinical outcomes and commercial success, enabling the reduction in overall manufacturing costs … through the use of BLFS products as HypoThermosol and CryoStor are recognized as critical reagents.

    Markets are closed today <Monday>, as a major hurricane swamps the eastern seaboard. BLFS closed on Friday, 10/26 at $0.27 up $0.01 or +3.85%. Excerpting, from Friday's mid-day … I continue to reiterate BLFS as a BUY … as BLFS "HIT" my short-term hurdle in a very down dropping market …to $0.33 with a minor retreat and … as I "had" said … $0.30 for 11/15! Looking to the future <1-2 months or years end> … a $0.50 target would still be a very modest prognostication!

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Back To Henry McCusker's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

  • ImmunoCellular (OTC BB: IMUC) files to Sell $13.8M of Units via Cowen
    Nov 30, 2011
  • Mid-Day Movers: BioTime (AMEX: BTX), Cytori (CYTX), Geron (GERN), Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (KOOL)
    Oct 26, 2011
More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.